We are delighted to welcome Émilie to the position of COO at Santero therapeutics, where she will bring her expertise to accelerate the development of new solutions against antimicrobial resistance, and in particular antibiotics. Émilie has extensive experience in the research and preclinical development of anti-infectives. She previously held the position of Head of Non-Clinical Development at Nosopharm, where she contributed to the discovery and advancement of cutting-edge therapeutic innovations.
Her arrival marks a new stage for Santero therapeutics, which is currently entering a new “lead-optimization” development phase with a view to developing a new generation of antibiotics.
Welcome, Émilie! We look forward to building this new chapter in Santero's future together.